| Apr 18 |
Ovid Therapeutics to Present at the American Academy of Neurology 71st Annual Meeting |
| Apr 2 |
Sangamo Therapeutics and AVEO Pharmaceuticals among healthcare gainers; Advaxis and Evoke Pharma among losers |
| Apr 2 |
MNKD, TTM among premarket gainers |
| Mar 28 |
Ovid Therapeutics announces management changes |
| Mar 28 |
Ovid Therapeutics Announces Senior Management Changes to Align Expertise with Advancing Clinical Stage Pipeline |
| Mar 21 |
Ovid Therapeutics Announces Appointment of Pharmaceutical Veteran, Thomas Perone, as Senior Vice President, General Counsel and Corporate Secretary |
| Mar 7 |
Ovid Therapeutics reports Q4 results |
| Mar 7 |
Ovid Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results |
| Mar 4 |
Ovid Therapeutics to Present at the Cowen and Company 39th Annual Healthcare Conference on Monday, March 11 |
| Feb 20 |
Why A Secondary Offering Is Often Negative For Stocks |
| Feb 20 |
Mid-Afternoon Market Update: Crude Oil Up 1.5%; Kandi Technologies Shares Spike Higher |
| Feb 20 |
54 Stocks Moving In Wednesday's Mid-Day Session |
| Feb 20 |
Mid-Day Market Update: LeMaitre Vascular Surges Following Strong Q4 Results; Sienna Biopharmaceuticals Shares Slide |
| Feb 20 |
Midday movers and shakers |
| Feb 20 |
LeMaitre Vascular leads healthcare gainers; CHF Solutions and Intercept Pharmaceuticals among losers |
| Feb 20 |
Ovid Therapeutics Announces Pricing of $30 Million of Securities in Concurrent Public Offerings of Common and Preferred Stock |
| Feb 20 |
The Daily Biotech Pulse: Teva Settles With FTC, Setback For Merck In Liver Cancer Trial, Sienna Biopharma Offering |
| Feb 19 |
Ovid down 22% after hours on equity offering |
| Feb 19 |
Ovid Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock |
| Feb 15 |
The Daily Biotech Pulse: Acorda Swings To Profit, Achaogen Offering, Bioblast Strikes Sanfilippo Syndrome Deal |
| Feb 7 |
Zynerba Stock Is Marijuana-Adjacent Play Worth a Look |
| Dec 28 |
The Daily Biotech Pulse: Opko Settles With SEC, Obalon Inks Financing Deals, Harpoon Files For IPO |
| Dec 25 |
How Much Of Ovid Therapeutics Inc. (NASDAQ:OVID) Do Insiders Own? |
| Dec 21 |
The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial |
| Dec 20 |
The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum |
